{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:53:37Z","timestamp":1782863617197,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00330-015-3729-9","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T04:11:21Z","timestamp":1430107881000},"page":"3348-3353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Volume-based quantitative FDG PET\/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery"],"prefix":"10.1007","volume":"25","author":[{"given":"H. A.","family":"Vargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Micc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hricak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"3729_CR1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","volume":"374","author":"BT Hennessy","year":"2009","unstructured":"Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371\u20131382","journal-title":"Lancet"},{"issue":"Suppl 2","key":"3729_CR2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1525-1438.2003.13357.x","volume":"13","author":"MJ Piccart","year":"2003","unstructured":"Piccart MJ, Bertelsen K, Stuart G et al (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13(Suppl 2):144\u2013148","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 7","key":"3729_CR3","doi-asserted-by":"crossref","first-page":"vii16","DOI":"10.1093\/annonc\/mdr421","volume":"22","author":"J Rochon","year":"2011","unstructured":"Rochon J, du Bois A (2011) Clinical research in epithelial ovarian cancer and patients' outcome. Ann Oncol 22(Suppl 7):vii16\u2013vii19","journal-title":"Ann Oncol"},{"key":"3729_CR4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/fon.12.112","volume":"8","author":"KH Baumann","year":"2012","unstructured":"Baumann KH, Wagner U, du Bois A (2012) The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol 8:1135\u20131147","journal-title":"Future Oncol"},{"key":"3729_CR5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21:289\u2013295","journal-title":"Int J Gynecol Cancer"},{"key":"3729_CR6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112:265\u2013274","journal-title":"Gynecol Oncol"},{"key":"3729_CR7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M, Trimble E, Tinker A et al (2011) Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 21:771\u2013775","journal-title":"Int J Gynecol Cancer"},{"key":"3729_CR8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00330-010-1886-4","volume":"20","author":"R Forstner","year":"2010","unstructured":"Forstner R, Sala E, Kinkel K, Spencer JA (2010) ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 20:2773\u20132780","journal-title":"Eur Radiol"},{"key":"3729_CR9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","volume":"71","author":"P Gu","year":"2009","unstructured":"Gu P, Pan LL, Wu SQ, Sun L, Huang G (2009) CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 71:164\u2013174","journal-title":"Eur J Radiol"},{"key":"3729_CR10","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1245\/s10434-011-2153-x","volume":"19","author":"HH Chung","year":"2012","unstructured":"Chung HH, Kwon HW, Kang KW et al (2012) Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 19:1966\u20131972","journal-title":"Ann Surg Oncol"},{"key":"3729_CR11","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/IGC.0b013e318260a905","volume":"22","author":"J Yoo","year":"2012","unstructured":"Yoo J, Choi JY, Moon SH et al (2012) Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18\u00a0F-fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer 22:1226\u20131233","journal-title":"Int J Gynecol Cancer"},{"key":"3729_CR12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2013.01.017","volume":"129","author":"IA Burger","year":"2013","unstructured":"Burger IA, Vargas HA, Donati OF et al (2013) The value of 18\u00a0F-FDG PET\/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecol Oncol 129:586\u2013592","journal-title":"Gynecol Oncol"},{"key":"3729_CR13","doi-asserted-by":"crossref","unstructured":"Sala E, Kataoka M, Pandit-Taskar N et al (2010) Recurrent ovarian cancer: contrast-enhanced CT and PET\/CT can accurately localize tumor recurrence and to predict patients\u2019 survival. Radiology 257(1):125\u2013134","DOI":"10.1148\/radiol.10092279"},{"key":"3729_CR14","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F","volume":"80","author":"YE Erdi","year":"1997","unstructured":"Erdi YE, Mawlawi O, Larson SM et al (1997) Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80:2505\u20132509","journal-title":"Cancer"},{"key":"3729_CR15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00259-008-0776-3","volume":"35","author":"K Kitajima","year":"2008","unstructured":"Kitajima K, Murakami K, Yamasaki E et al (2008) Performance of integrated FDG-PET\/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET\/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 35:1439\u20131448","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3729_CR16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2005.02.029","volume":"31","author":"C Nanni","year":"2005","unstructured":"Nanni C, Rubello D, Farsad M et al (2005) (18)F-FDG PET\/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 31:792\u2013797","journal-title":"Eur J Surg Oncol"},{"key":"3729_CR17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1148\/radiol.2332031800","volume":"233","author":"S Sironi","year":"2004","unstructured":"Sironi S, Messa C, Mangili G et al (2004) Integrated FDG PET\/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 233:433\u2013440","journal-title":"Radiology"},{"key":"3729_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","volume":"105","author":"MM Thrall","year":"2007","unstructured":"Thrall MM, DeLoia JA, Gallion H, Avril N (2007) Clinical use of combined positron emission tomography and computed tomography (FDG-PET\/CT) in recurrent ovarian cancer. Gynecol Oncol 105:17\u201322","journal-title":"Gynecol Oncol"},{"key":"3729_CR19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2008.08.027","volume":"112","author":"MJ Fulham","year":"2009","unstructured":"Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M (2009) The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 112:462\u2013468","journal-title":"Gynecol Oncol"},{"key":"3729_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","volume":"103","author":"B Simcock","year":"2006","unstructured":"Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ (2006) The impact of PET\/CT in the management of recurrent ovarian cancer. Gynecol Oncol 103:271\u2013276","journal-title":"Gynecol Oncol"},{"key":"3729_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2007.07.082","volume":"108","author":"M Soussan","year":"2008","unstructured":"Soussan M, Wartski M, Cherel P et al (2008) Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 108:160\u2013165","journal-title":"Gynecol Oncol"},{"key":"3729_CR22","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933\u20131939","journal-title":"Cancer"},{"key":"3729_CR23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.nucmedbio.2014.02.006","volume":"41","author":"IA Burger","year":"2014","unstructured":"Burger IA, Vargas HA, Apte A et al (2014) PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nucl Med Biol 41:410\u2013418","journal-title":"Nucl Med Biol"},{"key":"3729_CR24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/MNM.0000000000000045","volume":"35","author":"IA Burger","year":"2014","unstructured":"Burger IA, Vargas HA, Beattie BJ et al (2014) How to assess background activity: introducing a histogram-based analysis as a first step for accurate one-step PET quantification. Nucl Med Commun 35:316\u2013324","journal-title":"Nucl Med Commun"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-015-3729-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-015-3729-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-015-3729-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:59:54Z","timestamp":1559044794000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-015-3729-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3729"],"URL":"https:\/\/doi.org\/10.1007\/s00330-015-3729-9","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]}}}